ANGPTL4 protein therapy for chronic kidney disease
Recombinant hANGPTL4 and CKD
['FUNDING_R01'] · RUSH UNIVERSITY MEDICAL CENTER · NIH-11235866
This project looks at a modified ANGPTL4 protein as a possible way to lower protein in the urine and protect kidneys in people with diabetic kidney disease or FSGS.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | RUSH UNIVERSITY MEDICAL CENTER (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-11235866 on ClinicalTrials.gov |
What this research studies
Researchers are testing a modified human ANGPTL4 protein (called 8520) in laboratory and rat models to see if it can reduce protein loss in the urine and slow kidney damage. They will give 8520 to diabetic and focal segmental glomerulosclerosis (FSGS) rat models alone and together with ACE inhibitors, then measure kidney function (GFR/inulin clearance), proteinuria, and kidney tissue changes. The team is also studying how 8520 interacts with integrins in tiny kidney blood vessels to understand how it prevents cell death and fibrosis. If the animal and mechanistic results are strong, the work is meant to support moving this approach toward human testing.
Who could benefit from this research
Good fit: Adults with diabetic kidney disease or focal segmental glomerulosclerosis who have ongoing proteinuria despite standard treatments would be the most relevant candidates for future trials.
Not a fit: People with non-glomerular causes of kidney failure (for example polycystic kidney disease) or those already on dialysis are unlikely to benefit from this early-stage program.
Why it matters
Potential benefit: If successful, this approach could reduce proteinuria and slow progression toward end-stage kidney disease, preserving kidney function for people with diabetic nephropathy or FSGS.
How similar studies have performed: Prior preclinical studies with ANGPTL4 variants have shown reduced proteinuria and preserved GFR in animal models, but testing in people remains novel.
Where this research is happening
CHICAGO, UNITED STATES
- RUSH UNIVERSITY MEDICAL CENTER — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHUGH, SUMANT SINGH — RUSH UNIVERSITY MEDICAL CENTER
- Study coordinator: CHUGH, SUMANT SINGH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Adult-Onset Diabetes Mellitus